Arbutus Biopharma Corporation
ABUS
$5.16
-$0.02-0.39%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 181.72M | 191.45M | 14.08M | 14.61M | 15.42M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 181.72M | 191.45M | 14.08M | 14.61M | 15.42M |
| Cost of Revenue | 17.80M | 20.40M | 25.24M | 29.05M | 37.54M |
| Gross Profit | 163.92M | 171.04M | -11.16M | -14.44M | -22.12M |
| SG&A Expenses | 16.49M | 15.95M | 15.89M | 16.92M | 18.41M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.29M | 36.35M | 41.13M | 45.96M | 55.95M |
| Operating Income | 147.43M | 155.09M | -27.05M | -31.36M | -40.53M |
| Income Before Tax | 153.05M | 160.72M | -33.50M | -42.28M | -54.25M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 153.05 | 160.72 | -33.50 | -42.28 | -54.25 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 153.05M | 160.72M | -33.50M | -42.28M | -54.25M |
| EBIT | 147.43M | 155.09M | -27.05M | -31.36M | -40.53M |
| EBITDA | 147.47M | 155.14M | -26.69M | -30.67M | -39.52M |
| EPS Basic | 0.79 | 0.83 | -0.18 | -0.22 | -0.29 |
| Normalized Basic EPS | 0.49 | 0.51 | -0.08 | -0.09 | -0.12 |
| EPS Diluted | 0.78 | 0.82 | -0.18 | -0.23 | -0.29 |
| Normalized Diluted EPS | 0.48 | 0.51 | -0.08 | -0.09 | -0.12 |
| Average Basic Shares Outstanding | 775.37M | 769.45M | 766.39M | 763.74M | 760.96M |
| Average Diluted Shares Outstanding | 776.82M | 771.75M | 767.24M | 764.59M | 761.81M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |